- Home
- ADT vs JAZZ Comparison
ADT vs JAZZ Comparison
Compare ADT & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADT
- JAZZ
- Stock Information
- Founded
- ADT 1874
- JAZZ 2003
- Country
- ADT United States
- JAZZ Ireland
- Employees
- ADT N/A
- JAZZ N/A
- Industry
- ADT Diversified Commercial Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- ADT Consumer Discretionary
- JAZZ Health Care
- Exchange
- ADT Nasdaq
- JAZZ Nasdaq
- Market Cap
- ADT 7.0B
- JAZZ 7.1B
- IPO Year
- ADT 2018
- JAZZ 2007
- Fundamental
- Price
- ADT $8.76
- JAZZ $124.43
- Analyst Decision
- ADT Buy
- JAZZ Strong Buy
- Analyst Count
- ADT 5
- JAZZ 12
- Target Price
- ADT $9.34
- JAZZ $182.75
- AVG Volume (30 Days)
- ADT 10.3M
- JAZZ 879.8K
- Earning Date
- ADT 10-23-2025
- JAZZ 08-05-2025
- Dividend Yield
- ADT 2.51%
- JAZZ N/A
- EPS Growth
- ADT N/A
- JAZZ N/A
- EPS
- ADT 0.68
- JAZZ N/A
- Revenue
- ADT $5,058,741,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- ADT $6.18
- JAZZ $5.65
- Revenue Next Year
- ADT $4.23
- JAZZ $5.79
- P/E Ratio
- ADT $12.89
- JAZZ N/A
- Revenue Growth
- ADT 6.58
- JAZZ 4.52
- 52 Week Low
- ADT $6.68
- JAZZ $95.49
- 52 Week High
- ADT $8.86
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- ADT 56.81
- JAZZ 67.73
- Support Level
- ADT $8.60
- JAZZ $122.50
- Resistance Level
- ADT $8.86
- JAZZ $117.21
- Average True Range (ATR)
- ADT 0.16
- JAZZ 2.65
- MACD
- ADT 0.01
- JAZZ 0.92
- Stochastic Oscillator
- ADT 80.77
- JAZZ 89.49
About ADT ADT Inc.
ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name. The company segments include Consumer and Small Business (CSB).
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.